Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.
Source link
2025-03-28
A World of Free Speech
Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.
Source link